GlassScriptPhysician profile
John Cozart
NPI 1952309262
$5,636.76
in general payments reported to CMS, 2019-2025
26 companies · $508 in 2025
The $508 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $670 · 2021: $1,642 · 2022: $960 · 2023: $512 · 2024: $539 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,886.03 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Gilead Sciences, INC. | $900.74 | 2019-2025 | |
| Janssen Biotech, INC. | $743.76 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $598.63 | 2019-2022 | |
| Pfizer INC. | $493.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.86 | 2019-2022 | |
| Celgene Corporation | $89.43 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $70.39 | 2021 | |
| Braintree Laboratories, INC. | $66.95 | 2020-2021 | |
| Allergan, INC. | $61.31 | 2019-2020 | |
| Evoke Pharma, INC. | $49.51 | 2021 | |
| Merck Sharp & Dohme LLC | $40.64 | 2021-2024 | Dificid |
| Mauna Kea Technologies, INC. | $39.43 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $34.91 | 2019 | |
| Boston Scientific Corporation | $34.56 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.19 | 2023 | |
| Amgen INC. | $31.12 | 2021 | |
| Intercept Pharmaceuticals, INC. | $26.14 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $21.86 | 2021 | |
| Myriad Genetic Laboratories, INC. | $21.00 | 2021 | |
| Lilly USA, LLC | $19.57 | 2024 | Omvoh |
| Medtronic, INC. | $19.40 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.02 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $16.08 | 2024 | Resmetirom |
| Ucb, INC. | $11.70 | 2019 | |
| Organon LLC | $11.56 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cozart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.